The Changing Landscape of NSCLC: MET Inhibitors - a podcast by ReachMD

CME credits: 0.25

Valid until: 29-04-2021

Claim your CME credit at https://reachmd.com/programs/cme/the-changing-landscape-of-nsclc-met-inhibitors/11312/

Approximately 3 to 4 percent of the non-small cell lung cancer patient population as a whole harbors MET exon 14 skipping mutations that result in increased MET kinase protein levels and a constitutively active pathway. There is increasing excitement that these mutations, as well as MET gene amplification, can be specifically targeted with MET-directed approaches. Join us as Drs. Everett Vokes and Ross Camidge discuss both the dysregulation of the MET pathway in non-small cell lung cancer and the therapeutic potential of small molecule MET kinase inhibitors.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD